The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Novartis (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, achieved the ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Roche (RHHBY) and Novartis (NVS) are scheduled to meet with Swiss officials this week amid U.S. tariff threats on pharma ...

Novartis ( (NVS)) has provided an update. On August 11, 2025, Novartis announced that its Phase III clinical trials for ianalumab, a novel treatment for Sjögren’s disease, successfully met their ...

Novartis has been evaluating a bid for Avidity, which had a market value of about $5.8bn at market close on Wednesday, and ...

One near-term rival is Johnson & Johnson's FcRn inhibitor nipocalimab, which started a phase 3 programme last December.

Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...